Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended September 30, 2012. The company is an Australian biotechnology entity reporting under Appendix 4C for entities admitted on the basis of commitments. The filing was signed on October 29, 2012.
Key Financial Metrics
| Metric | Value (AUD '000) |
|---|---|
| Revenue (Receipts from customers) | 0 |
| Net Operating Cash Flow | (1,438) |
| Net Investing Cash Flow | (10) |
| Net Financing Cash Flow | 1,890 |
| Net Increase in Cash | 442 |
| Cash at End of Quarter | 6,003 |
| Debt/Borrowings | 0 |
The company reported no revenue and no borrowings. Operating outflows were primarily driven by research and development ($740,000) and staff costs ($352,000). Financing activities included proceeds from share issues of $1,926,000, offset by $36,000 in capital raising costs.
Material Changes and Liquidity
Cash reserves increased from $5,637,000 at the beginning of the quarter to $6,003,000 at the end, primarily due to equity financing. There were no material changes in debt levels as no loan facilities were utilized. The filing notes a subsequent event where the company raised an additional $6,012,500 after the quarter-end date.
Outlook, Risks, and Management Commentary
The filing contains no specific forward-looking guidance, management commentary on future prospects, or detailed risk factors beyond the standard disclosure of cash flow activities. The company remains in a pre-revenue stage with cash burn funded by equity issuance. No unusual items or contingencies were disclosed in the text provided.
Investor Verification Checklist
- Verify the identity of the registrant (Prana Biotechnology Limited) against the metadata name (Altery Therapeutics Ltd).
- Confirm the utilization of the $6,012,500 raised subsequent to September 30, 2012.
- Monitor the burn rate given zero revenue and significant R&D expenditures.
- Check for any new debt facilities or changes in capital structure not reflected in this quarterly snapshot.